Latest News
-
Honasa Consumer to Strengthen Operations by Merging Fusion Cosmeceutics and Just4Kids -
Wipro Reports 7.8% Decline in Q4 Net Profit; CEO Highlights Economic Challenges -
IREDA Hits Record Annual PAT of Rs 1,252 Cr in FY24; Q4 Profits Up by 33% -
Massive Employee Exodus Hits India's Top IT Companies in FY23-24 -
Air India Enhances Operational Efficiency with New Crew Management System -
BlackRock Acquires Shares in Electrosteel Castings and PTC India for Rs 207 Crore -
IndiGo Enhances Domestic Routes with Direct Chennai-Durgapur Flights -
Tesla to Recall Nearly 4,000 Cybertrucks Over Accelerator Pedal Fault -
Reliance, ONGC, Tata, Adanis: Energy Stocks Didn't Get The Memo Of Bears, Up 12% In 30-Days; 10 Stocks To BUY -
Sebi to Enhance Price Discovery for Firms Trading Below Book Value
Motilal Oswal Tuesday Stock Ideas: Buy 5 Mid Cap, Small Cap Stocks To Get Up To 46% Return
Motilal Oswal, in its latest report, has suggested investors to invest in 5 stocks promising good returns. These stocks are Angel One, Eris Lifesciences, Gland Pharma, Laurus Labs, and Brigade Enterprise. If you buy these stocks today, you can ger maximum return of 46%. Check key details below:
| Name of company | Potential return |
|---|---|
| Laurus Labs Ltd | 46% |
| Brigade Enterprise Ltd | 45% |
| Angel One Ltd | 43% |
| Gland Pharma Ltd | 42% |
| Eris Lifesciences Ltd | 31% |
1. Buy Laurus Labs Ltd
Motilal Oswal is bullish on the pharmaceuticals stock and recommended buy with a target price of Rs 610 apiece. The current market price of the stock is Rs 417 apiece with an intraday fall of 0.62%.
If you buy Laurus Labs Ltd today, you can get a return of 46%. It has a market capitalisation of Rs 22,458 crore. The pharmaceuticals sector stock has given maximum return of 515% in last 3-years and 303% in last 5-years.
The company on September 30, 2022 declared a consolidated total income of Rs 1577 crore, up 2% from last quarter total income of Rs 1540 crore.
2. Buy Brigade Enterprise
Motilal Oswal is optimistic on the stock and assigned buy call with a target price of Rs 720 apiece. The current market price of the stock is Rs 495 apiece with an intraday fall of 0.74%. The company has a market capitalisation of Rs 11,430 crore.
If you buy the stock now, you can get maximum 45% return. The stock has given maximum 151% return in last 5-years. It declared its consolidated total income on September 30, 2022 at 912 crore, down .88%.
3. Buy Angel One Ltd
Motilal Oswal has recommended investors to buy Angel One Ltd with a target price of Rs 2200 apiece. The current market price of the stock is Rs 1541 apiece with an intraday fall of 0.26%.
If you buy Angel One now, it can offer you 43% potential return. The stock operates in Financial Services sector and has given multibagger returns with maximum return at 457% in last 5-years. The company has a market capitalisation of Rs 12,826 crore.
It declared its consolidated total income on September 30, 2022 at 745 crore, up over 8% from last quarter total income of Rs 686 crore.
4. Buy Gland Pharma Ltd
Motilal Oswal has included this stock under the category of "Buy" with a target price of Rs 2470 apiece. The current market price of Gland Pharma is Rs 1742 apiece.
If you buy Gland Pharma Ltd today, you can get a return of 42%. The company has a market capitalisation of Rs 28,697 crore. It operates in pharmaceuticals sector and has fallen 51% in last 1-year.
It declared it consolidated total income as on September 30, 2022 at Rs 1,110 crore, up 19% from last quarter total income of Rs 931 crore.
5. Buy Eris Lifesciences Ltd
The analyst has given buy call to Eris Lifesciences with a target price of Rs 860 apiece. The current market price of the stock is Rs 657 apiece with an intraday decline of 0.27%.
If you buy Eris Lifesciences Ltd now, you can get a return of 31%. It has a market capitalisation of Rs 8947 crore. The pharmaceuticals sector stock has given maximum 38% return in last 5-years.
It declared its consolidated total income at Rs 465 crore as on September 30, 2022, up 16% from last quarter total income of Rs 401 crore.
Disclaimer
The stocks have been picked from the brokerage report of Motilal Oswal. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.
